Prof Laura-Maria Krabbe (University of Münster Medical Center, Münster, Germany), Prof Karim Fizazi (Institut Gustave Roussy, Villejuif, France) and Prof Johann De Bono (The Institute of Cancer Research, London, UK) discuss the advances in prostate cancer in the last 10 years and offer a glimpse of the future.
Initially, Prof Krabbe discusses abiraterone and enzalutamide in mCRPC (post docetaxel and pre docetaxel) and their impact for mCRPC care. Prof Fizazi and Prof De Bono then discuss the movement of oral substances (including darolutamide and apalutamide) into earlier settings (mHSPC and m0CRPC) to maximise their efficacy. They further discuss the PEACE-1 trial, STAMPEDE trial, PARP inhibition in DDR mutant tumours and PSMA-radioligand therapy.
Prof Krabbe mentions the use of AKT inhibitors to increase the portfolio of molecularly guided therapies. They also discuss the future role of immunotherapy in prostate cancer and how clinicians can care for their patients in a more complex landscape in the future. They conclude by discussing advanced PCA as a chronic disease.
|Treatments introduced for prostate cancer in the last decade|
|Doublet therapy in earlier settings to maximise efficacy|
|Triplet therapy and PEACE-1 Trial|
|Approval of drugs|
|PARP inhibition and PSMA-radioligand therapy|
|Prostate cancer as chronic disease|
This programme has been supported by an unrestricted educational grant from Janssen.